Evidence map›Paper›PMID 41091754›Full record

ArticlePloS one2025

Evaluation of GDH and HDP as novel serological biomarkers for Plasmodium falciparum malaria diagnosis across varying parasitemia and transmission settings in India.

Amreen Ahmad, Shrikant Nema, Kushagri Arora, Ruhi Sikka, Akansha Singh, Sri Krishna, Mrigendra Pal Singh, Anil Kumar Verma, Nitika Nitika, Anup R Anvikar and 2 more

Abstract read
In one paragraph

Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Amreen AhmadICMR-National Institute of Research in Tribal Health, Jabalpur, Madhya Pradesh, India.
Shrikant NemaICMR-National Institute of Malaria Research, Dwarka, Delhi, India.
Kushagri AroraDepartment of Biotechnology, Institute of Applied Sciences and Humanities, GLA University, Mathura, India.
Ruhi SikkaDepartment of Biotechnology, Institute of Applied Sciences and Humanities, GLA University, Mathura, India.
Akansha SinghICMR-National Institute of Malaria Research, Dwarka, Delhi, India.
Sri KrishnaICMR-National Institute of Research in Tribal Health, Jabalpur, Madhya Pradesh, India.
Mrigendra Pal SinghICMR-National Institute of Malaria Research, Dwarka, Delhi, India.
Anil Kumar VermaICMR-National Institute of Research in Tribal Health, Jabalpur, Madhya Pradesh, India.
Nitika NitikaICMR-National Institute of Malaria Research, Dwarka, Delhi, India.
Anup R AnvikarICMR-National Institute of Malaria Research, Dwarka, Delhi, India.
Himanshu GuptaDepartment of Biotechnology, Institute of Applied Sciences and Humanities, GLA University, Mathura, India.
Praveen Kumar BhartiICMR-National Institute of Malaria Research, Dwarka, Delhi, India.ORCID https://orcid.org/0000-0003-1511-7503

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Malaria diagnosis has progressed significantly with the introduction of Rapid Diagnostic Tests (RDTs) targeting Histidine-Rich Protein 2 (HRP2), Lactate dehydrogenase (LDH), and aldolase. However, challenges remain, such as the presence of Plasmodium falciparum histidine-rich protein 2 (pfhrp2) gene deletions and reduced sensitivity in regions with low parasitemia. This study evaluates antibody responses to novel biomarkers-glutamate dehydrogenase (GDH) and Heam detoxification protein (HDP)-in comparison to conventional antigens (HRP2, LDH, and aldolase) across different infection, transmission settings, and parasitemia conditions. We analyzed plasma samples from 928 participants, including 886 P. falciparum-positive cases, using enzyme-linked immunosorbent assay. Our results revealed antibody levels against all studied peptides clear differentiation between malaria-positive and negative samples, with Receiver Operating Characteristic (ROC) curve analysis showing high diagnostic accuracy (Area under the ROC curve > 96%) for detecting P. falciparum infection. However, the sensitivity and specificity for differentiating between endemicity or parasitemia groups were limited for certain peptides. Specifically, GDH2 and HRP2 effectively distinguished parasitemia levels, while GDH2, HDP2, and LDH showed promise in distinguishing between varying endemicity levels. These findings suggest that GDH and HDP have significant potential as reliable serological biomarkers for malaria detection. However, further studies are needed to refine their application in categorizing endemicity and parasitemia. This research highlights the need for adaptable diagnostic tools to address the complex challenges of malaria in endemic regions.

Indexed as

Glutamate DehydrogenaseMalaria, FalciparumParasitemiaPlasmodium falciparumProtozoan ProteinsAdolescentAdultAntibodies, ProtozoanAntigens, ProtozoanBiomarkersChildChild, PreschoolEnzyme-Linked Immunosorbent AssayFemaleHumansIndiaAntibodies, ProtozoanAntigens, ProtozoanBiomarkersGlutamate DehydrogenaseHRP-2 antigen, Plasmodium falciparumL-Lactate DehydrogenaseProtozoan Proteins

Identifiers

PMID41091754
PMCPMC12527120

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.